domain protein-1/hypoxia-inducible factor-2α (EPAS-1/ HIF-2α) is a catabolic transcription factor that regulates osteoarthritis (OA) cartilage destruction. Objectives: In this study, we examined whether microRNA-365 (miR-365) affects interleukin (IL)-1β-induced expression of catabolic factors in chondrocytes via regulation of HIF-2α. Methods: Total RNA was isolated from normal and OA cartilage tissues and human chondrocytes. miR-365 expression was quantified by TaqMan assay. The effects of miR-365 on HIF-2α and HIF-2α-modulated genes were assessed by quantitative real-time reverse polymerase chain reaction (qRT-PCR), Western blot analysis, and enzyme-linked immunosorbent assay (ELISA). Direct interaction of miR-365 with the 3' untranslated region (UTR) of HIF-2α mRNA was examined using a luciferase reporter assay. Nitrite concentration was measured in culture medium using a Griess assay. Results: miR-365 levels were significantly decreased in human OA cartilage relative to normal cartilage. Overexpression of miR-365 significantly suppressed IL-1β-induced expression of HIF-2α in human articular chondrocytes. Pharmacological inhibition of various IL-1β-associated signaling pathways revealed mitogen-activated protein kinase and nuclear factor-κB as the primary pathways driving IL-1β-mediated decreases in miR-365 and subsequent increase in HIF-2α expression. Using a luciferase reporter assay encoding the 3'UTR of human HIF-2α mRNA, we showed that overexpression of miR-365 significantly suppressed IL-1β-induced up-regulation of HIF-2α. Furthermore, miR-365 overexpression significantly suppressed IL-1β-induced expression of catabolic factors, including cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloproteinase-1, -3 and -13, and nitric oxide (NO) production in chondrocytes. Background: ROC study provided data to manage rheumatoid arthritis (RA) treatment after a failure to a first TNF blocker (1). We previously reported that high circulating TNF bioactivity was associated with good clinical response (2). Objectives: To explore ability of TNF bioactivity to predict response to second TNF blocker. Methods: Here, we assessed TNF bioactivity in 130 RA patients from the group rotation to a second TNF blocker at the time of randomisation and after 6 months. Clinical and biological data were recorded at baseline and 6 month with Eular response assessed at 6 month. TNF bioactivity was assessed with HEK-Dual TNF cells adapted from our previous work (2). Due to non-normalised distribution, non parametrical analysis were performed.
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Conclusions
Results: Baseline circulating TNF bioactivity was similar according to Eular response. However, circulating TNF bioactivity at 6 month was associated with clinical response with low TNF bioactivity in responders. A ROC analysis suggested a cut-off at 0.320 with a sensitivity at 92% and a specificity at 41%. Conclusions: After a failure of a first TNF blocker, circulating TNF bioactivity is not able to predict response to a second TNF blocker despite a lower level in responders compared to non-responders. Background: A main challenge in spondyloartritis (SpA) management was the availability of reliable biomarkers related with disease activity, or predicting joint damage and the response to treatment. Although erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are currently used as biomarkers for disease activity, they lack sensitivity, specificity and reproducibility. With the understanding of SpA pathogenesis, additional biomarkers like metalloproteinase 3 (MMP-3), interleukin (IL)-1a, IL-6, lipopolysaccharide-binding protein (LBP), tumour necrosis factor a (TNFa), macrophage colony stimulating factor (M-CSF), interferon gamma (INF-g), IL-17 and IL-23, had been proposed Objectives: We aimed to evaluate the associations of MMP-3, IL-1a, IL-6, M-CSF, LPB, IL-17 and IL-23 levels in SpA patients positive for HLA-B27 or HLA-B15 Methods: 178 patients (100 men and 78 women) with SpA according to ASAS criteria were included in the study. HLA typing was performed by PCR using the Biorad ® HLA-SSP ABDR plates. The levels of TNFa, IL-1a, IL-6, INF-g and IL-17 were measured by a cytometric bead-array (CBA Flex Set) using a FACS Canto II Flow CytometerÔ. Enzyme-linked immunosorbent assay (ELISA) was used to determine serum levels of IL-23, M-CSFand MMP-3. CRP and LBP levels were measured by chemiluminescence. Statistical analysis was made with SPSS v19. For comparison of quantitative variables with a normal distribution we used the Student's t-test. Categorical variables were presented in frequency charts and percentages, and the Chi-squared test and Fisher's exact test were used when necessary, for comparing groups. Two-tailed P-value <0.05 was considered statistically significant Results: Of the 178 patients, 70 were positive for HLA-B27, 34 for HLA-B15 and 74 had other HLA-B. According to ASAS classification criteria, 152 patients had axial SpA (axSpA) manifestations, 161 had peripheral SpA (pSpA) manifestations, and 148 patients had mixed axial and peripheral manifestations. Figure 1 shows the mean levels of inflammatory serologic biomarkers in these subgroups of patients
Conclusions:
High levels of IL-17 and IL-23 were associated with the presence of HLA-B27, which mainly correlates with an axial presentation of the disease as compared to HLA-B15 patients. Accordingly, the genotype (presence of HLA-B27 or HLA-B15) and phenotype (axial or peripheral involvement) may help physicians when considering a targeted therapy of SpA patients with IL-17 inhibition in a context of personalized medicine Background: Although concern remains about the athero-thrombotic risk posed by COX-2-selective inhibitors (COXIBs), the recent PRECISION trial demonstrated non-inferiority of moderate dose celecoxib when compared to naproxen and ibuprofen with respect to cardiovascular safety, with fewer actual CV events recorded for celecoxib. Moreover, celecoxib proved significantly safer than either comparator in regard to gastrointestinal events 1 . Given the markedly different cardiovascular risk associated with celecoxib and rofecoxib, we investigated the hypothesis that, in addition to cyclo-oxygenase inhibition, celecoxib specifically activates COX-2-independent AMP kinase (AMPK) signalling to exert protective effects in the vascular endothelium. Objectives: To investigate COX-2-independent vasculoprotective signalling pathways activated by celecoxib in human endothelium.
Methods:
In vitro studies of celecoxib, rofecoxib, ibuprofen and naproxen were performed on human umbilical vein and human aortic endothelial cells (HUVEC and HAEC). Inhibition of signalling pathways was achieved using siRNA. The vascular effects of celecoxib in vivo were studied in C57Bl/6 mice fed celecoxib (1000 ppm) or control chow (48 hrs). Aortic tissue was snap-frozen and sections studied by immunofluorescence confocal microscopy. Results: At therapeutically relevant concentrations celecoxib (1-10μ M) induced the vasculoprotective protein heme oxygenase-1 (HO-1) in HUVEC and HAEC (EC) (p<0.01). In contrast, rofecoxib and the commonly used non-selective NSAIDs ibuprofen and naproxen failed to induce HO-1. Celecoxib derivative 2,5-dimethyl-celecoxib (DMC), which lacks COX-2 inhibition, also upregulated HO-1, implicating a COX-2-independent mechanism. Immunoblotting demonstrated that celecoxib and DMC induce AMPKα (Thr172) and CREB-1 (Ser133) phosphorylation leading to Nrf2 nuclear translocation (p<0.05). These responses were not seen with ibuprofen or naproxen, while siRNA depletion of AMPKα abrogated celecoxib-mediated CREB and Nrf2 activation (p<0.05). Acting via the same pathway, celecoxib induced additional cytoprotective genes including H-ferritin. In vivo, celecoxib similarly increased HO-1 and H-ferritin in murine aortic endothelium when compared to control-fed mice (p<0.05). Functionally, celecoxib treatment inhibited TNF-α-induced NF-κB p65 (Ser536) phosphorylation by increasing AMPK activity. This attenuated VCAM-1 upregulation via induction of HO-1, as revealed by HO-1 siRNA (p<0.05). Similarly, celecoxib prevented the IL-1-mediated increase of IL-6 mRNA (p<0.01). These responses were not seen with ibuprofen or naproxen. Conclusions: Celecoxib induces anti-inflammatory, anti-oxidant proteins HO-1 and H-ferritin in human vascular endothelium via a novel AMPK-CREB-Nrf2-dependent pathway. This mechanism may contribute to the important and marked differences in cardiovascular risk between celecoxib and rofecoxib. Understanding mechanisms underlying NSAID heterogeneity may ultimately lead to the development of safer anti-inflammatory drugs. 
